TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37925660

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 4404

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 4404

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 4404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4404

Group type: EXPERIMENTAL
Intervention: Tofacitinib (both dosages)
Number of subjects: 4404

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 4404
Study: 37925960

Group type: EXPERIMENTAL
Intervention: 1 mA tACS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mA tACS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall stimulation group
Number of subjects: 60
Study: 37926085

Group type: EXPERIMENTAL
Intervention: Non-contrast enhanced magnetic resonance imaging (MRI)
Number of subjects: 7
Study: 37926100

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Accelerated epirubicin
Number of subjects: 1281

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Standard epirubicin
Number of subjects: 1281
Study: 37926123

Group type: EXPERIMENTAL
Intervention: Remote skin testing and biophysical testing from birth to monitor skin barrier maturation.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Common filaggrin risk alleles screening.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Assessment of lipid/protein ratio and chymotrypsin-like activity at birth.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Transepidermal water loss measurement.
Number of subjects: 128
Study: 37926224

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 min) + overground gait training (40 min for 5 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham tDCS (30-s stimulation) + overground gait training (40 min for 5 days)
Number of subjects: 34
Study: 37926336

Group type: EXPERIMENTAL
Intervention: Urinary biomarkers (α-glutathione-S-transferase, albumin, cystatin C) measured at 27, 30, and 34 weeks' postmenstrual age
Number of subjects: 327

Group type: COMPARATOR
Intervention: Exploratory case-control study
Number of subjects: 327
Study: 37926429

Group type: EXPERIMENTAL
Intervention: 90° bend angle stylet
Number of subjects: 98

Group type: COMPARATOR
Intervention: 70° bend angle stylet
Number of subjects: 98
Study: 37926984

Group type: EXPERIMENTAL
Intervention: Positive End-Expiratory Pressure (PEEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FiO2
Number of subjects: 0
Study: 37927032

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study: 37927075

Group type: EXPERIMENTAL
Intervention: cPCV7 Coadministered with PCV13 at ages 2, 4, 6, and 12 months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: cPCV7 Separated given at ages 3, 5, 7, and 13 months, 3-5 weeks after PCV13
Number of subjects: 512

Group type: COMPARATOR
Intervention: PCV13 Control followed by a single supplemental dose of cPCV7 at 13 months
Number of subjects: 512
Study: 37927585

Group type: EXPERIMENTAL
Intervention: Subchronic supplementation of a standardised phospholipid carrier-based intervention
Number of subjects: 0
Study: 37927936

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine (GnP-NAT), 125 mg/m²
Number of subjects: 61
Study: 37928150

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Baseline NIHSS <20
Number of subjects: 378
Study: 37928335

Group type: EXPERIMENTAL
Intervention: Health App for Post-Pandemic Years (HAPPY)
Number of subjects: 814
Study: 37928434

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation (MSCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating miR-320b
Number of subjects: 0
Study: 37928473

Group type: EXPERIMENTAL
Intervention: AZVUDINE (FNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37928549

Group type: EXPERIMENTAL
Intervention: Tixagevimab/Cilgavimab 300 mg IV
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tixagevimab/Cilgavimab 300 mg IM
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tixagevimab/Cilgavimab 600 mg IV
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Regdanvimab 40 mg/kg IV
Number of subjects: 77
Study: 37928754

Group type: EXPERIMENTAL
Intervention: COMEX program (3-month participation, video-based dialysis chair exercises including aerobic and resistance exercises, educational and motivational components)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: COMEX program
Number of subjects: 17
Study: 37928891

Group type: EXPERIMENTAL
Intervention: Oral bemnifosbuvir (AT-527)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37928895

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (PC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nivolumab plus chemotherapy (NC)
Number of subjects: 3
Study: 37928920

Group type: EXPERIMENTAL
Intervention: Neuro-glasses (peripheral visual stimuli embedded in standard eyeglasses)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Neuro-glasses
Number of subjects: 108
Study: 37928922

Group type: COMPARATOR
Intervention: Metabolomic profiling using liquid chromatography-tandem mass spectrometry to quantify 54 metabolites.
Number of subjects: 499

Group type: COMPARATOR
Intervention: Subset of 42 biomarkers identified in autistic individuals.
Number of subjects: 499

Group type: COMPARATOR
Intervention: Hierarchical clustering of biomarkers.
Number of subjects: 499

Group type: COMPARATOR
Intervention: Metabolic changes associated with clusters.
Number of subjects: 499

Group type: COMPARATOR
Intervention: Association of autism severity and cognitive impairment with metabolic markers.
Number of subjects: 499
Study: 37928925

Group type: EXPERIMENTAL
Intervention: Relapse prevention (RP) therapy based on cognitive behavioral treatment (CBT), comprising five to seven 45-min sessions over a period of 5 to 7 weeks.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 111
Study: 37928934

Group type: EXPERIMENTAL
Intervention: Physical Activity Together for MS (PAT-MS) intervention, a 12-week dyadic behavioural intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control condition.
Number of subjects: 0
Study: 37929584

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 562

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 562
Study: 37929587

Group type: EXPERIMENTAL
Intervention: PCI+OMT
Number of subjects: 700

Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 700
Study: 37929602

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg daily
Number of subjects: 13970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 13970
Study: 37929615

Group type: EXPERIMENTAL
Intervention: End-tidal carbon dioxide (ETCO2) monitoring during CPR
Number of subjects: 234
Study: 37929672

Group type: EXPERIMENTAL
Intervention: Mirtazapine (target 45 mg)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Carbamazepine (target 300 mg)
Number of subjects: 244
Study: 37929764

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) score >300
Number of subjects: 1931

Group type: COMPARATOR
Intervention: No calcification
Number of subjects: 1931
Study: 37929770

Group type: EXPERIMENTAL
Intervention: Long-term home exercise program, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 37929782

Group type: EXPERIMENTAL
Intervention: Genetic variants rs9939224
Number of subjects: 12031
Study: 37929831

Group type: EXPERIMENTAL
Intervention: High-protein formula (≥ 2.5 g per 100 kcal)
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Standard-protein formula
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Low-protein formula
Number of subjects: 1185
Study: 37929840

Group type: COMPARATOR
Intervention: PDE5 inhibitors (PDE5i)
Number of subjects: 411
Study: 37929952

Group type: COMPARATOR
Intervention: NUC
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg plus NUC
Number of subjects: 238
Study: 37930156

Group type: EXPERIMENTAL
Intervention: Nemtabrutinib 65 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nemtabrutinib (varied doses 5 to 75 mg once daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Number of subjects: 48
Study: 37930231

Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane (PFHO) ophthalmic solution (MIEBO™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypotonic saline solution
Number of subjects: 0
Study: 37930244

Group type: EXPERIMENTAL
Intervention: High-dose protein (≥ 2.2 g/kg/d)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Usual-dose protein (≤ 1.2 g/kg/d)
Number of subjects: 425
Study: 37930283

Group type: EXPERIMENTAL
Intervention: Dog visits
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 37930478

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 37930669

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (2 mg/d or 3 mg/d)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study: 37930692

Group type: EXPERIMENTAL
Intervention: HABIT-ILE (50 hours over 2 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual motor activity (control group)
Number of subjects: 50
Study: 37930756

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study: 37930767

Group type: EXPERIMENTAL
Intervention: Web-based couple intervention (COMPANION) consisting of psychoeducation, mindfulness, and cognitive-behavioral exercises, supervised remotely by a trained therapist for 9 sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based couple intervention (COMPANION)
Number of subjects: 0
Study: 37930773

Group type: EXPERIMENTAL
Intervention: Information guide for adult kidney transplant patients
Number of subjects: 5
Study: 37930776

Group type: EXPERIMENTAL
Intervention: Transfemoral EVOQUE transcatheter TV replacement
Number of subjects: 176
Study: 37930781

Group type: EXPERIMENTAL
Intervention: Lumen voice-based coach delivering 8 problem-solving treatment sessions
Number of subjects: 42
Study: 37930786

Group type: EXPERIMENTAL
Intervention: Automated messaging for weight loss (6-12 months)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 40
Study: 37930792

Group type: EXPERIMENTAL
Intervention: Later scheduled start time
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Later schedule end time
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Activities extending beyond 10 pm
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Increased daily documented total activity time
Number of subjects: 223
Study: 37931065

Group type: EXPERIMENTAL
Intervention: Digital Single-Session Interventions (SSIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 0
Study: 37931185

Group type: EXPERIMENTAL
Intervention: Circulating tumor cell count-driven therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 37931304

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy - Taking it Further (MBCT-TiF)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Ongoing Mindfulness Practice (OMP)
Number of subjects: 164
Study: 37931334

Group type: EXPERIMENTAL
Intervention: Hatha Yoga intervention for 8 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 98
Study: 37931372

Group type: EXPERIMENTAL
Intervention: Maternal dietary cluster 1 (plant protein and fibers)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maternal dietary cluster 2 (animal protein)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-378 and 320 family miRNAs
Number of subjects: 60
Study: 37931445

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and etoposide (CP/ET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus carboplatin and etoposide (CP/ET)
Number of subjects: 0
Study: 37931480

Group type: EXPERIMENTAL
Intervention: eIMPACT intervention (internet cognitive-behavioral therapy [CBT], telephonic CBT, and select antidepressant medications)
Number of subjects: 216

Group type: COMPARATOR
Intervention: usual primary care
Number of subjects: 216
Study: 37931481

Group type: EXPERIMENTAL
Intervention: Patients with vertebrobasilar ischemia (VBI)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Controls (29 age- and sex-matched healthy persons)
Number of subjects: 107
Study: 37931629

Group type: EXPERIMENTAL
Intervention: Zibotentan combined with dapagliflozin
Number of subjects: 449

Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 449
Study: 37931632

Group type: EXPERIMENTAL
Intervention: Chemotherapy with pembrolizumab (n=222)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Chemotherapy alone (n=218)
Number of subjects: 440
Study: 37931634

Group type: EXPERIMENTAL
Intervention: Sparsentan (400 mg oral once daily)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Irbesartan (300 mg oral once daily)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 404

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 404
Study: 37931749

Group type: EXPERIMENTAL
Intervention: Healthy Low-Carbohydrate (HLC) diet
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Healthy Low-Fat (HLF) diet
Number of subjects: 448

Group type: COMPARATOR
Intervention: High Quality (HQ) and High Adherence (HA) subgroups
Number of subjects: 448

Group type: COMPARATOR
Intervention: Low Quality (LQ) and Low Adherence (LA) subgroups
Number of subjects: 448
Study: 37931967

Group type: EXPERIMENTAL
Intervention: ePRO digital health application combined with proactive follow-up by nurses
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual healthcare and a list of breast cancer information sources
Number of subjects: 205
Study: 37931968

Group type: EXPERIMENTAL
Intervention: Adolescent drive for thinness
Number of subjects: 887

Group type: COMPARATOR
Intervention: Persistently high weight trajectory
Number of subjects: 887
Study: 37932009

Group type: EXPERIMENTAL
Intervention: Remibrutinib (100 mg, one or two times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remibrutinib
Number of subjects: 0
Study: 37932258

Group type: EXPERIMENTAL
Intervention: BI 1467335 1 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BI 1467335 3 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BI 1467335 6 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BI 1467335 10 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BI 1467335 (≥3 mg)
Number of subjects: 81
Study: 37932443

Group type: EXPERIMENTAL
Intervention: Irinotecan dosage adjusted based on UGT1A1 polymorphisms, specifically 370 mg/m² for *1/*1 genotype.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Irinotecan dosage adjusted based on UGT1A1 polymorphisms.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard dose of irinotecan (180 mg/m²).
Number of subjects: 34
Study: 37932493

Group type: EXPERIMENTAL
Intervention: Peer-education intervention with booster training sessions
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Booster training sessions
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control networks
Number of subjects: 560
Study: 37932539

Group type: EXPERIMENTAL
Intervention: how
Number of subjects: 3665

Group type: EXPERIMENTAL
Intervention: why
Number of subjects: 3665

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 3665
Study: 37932589

Group type: EXPERIMENTAL
Intervention: mesoglycan 50 mg bid
Number of subjects: 650

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 650
Study: 37932609

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 296 MBq PET/CT
Number of subjects: 712
Study: 37932648

Group type: EXPERIMENTAL
Intervention: Preoperative plasma transforming growth factor beta 1 (TGF-β1) concentration
Number of subjects: 80
Study: 37932649

Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 76
Study: 37932650

Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation-derived mean arterial pressure targets ranging from 55 to 100 mm Hg.
Number of subjects: 42
Study: 37932730

Group type: EXPERIMENTAL
Intervention: Step 1: Messages sent through the health system patient portal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Step 2: Text message outreach to non-responders from Step 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Step 3: Clinician contact using a 'pend and send' tool in the EHR for non-responders from Step 2
Number of subjects: 0
Study: 37932739

Group type: EXPERIMENTAL
Intervention: 10 mg/kg suramin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 20 mg/kg suramin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 37932787

Group type: EXPERIMENTAL
Intervention: POINCARE-2 strategy (daily weighing over 14 days, restriction of fluid intake, administration of diuretics, and/or ultrafiltration)
Number of subjects: 1361

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1361
Study: 37932812

Group type: EXPERIMENTAL
Intervention: Volume expansion (500-mL saline infusion)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Norepinephrine dose increase
Number of subjects: 69
Study: 37932848

Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/MRI
Number of subjects: 40
Study: 37932961

Group type: EXPERIMENTAL
Intervention: Plasma Aβ42/Aβ40
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphorylated variant p-tau181 ratio (p-tau181/np-tau181)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphorylated variant p-tau217 ratio (p-tau217/np-tau217)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma Predicted Centiloid (PPC) model including p-tau217/np-tau217, Aβ42/Aβ40, age, and apolipoprotein E
Number of subjects: 0
Study: 37933185

Group type: EXPERIMENTAL
Intervention: mHealth platform with automated text notifications on days 1, 3, 5, and 7
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: mHealth platform
Number of subjects: 1525
Study: 37933187

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 870
Study: 37933196

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37933546

Group type: EXPERIMENTAL
Intervention: Intervention group (survey administered)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no survey administered)
Number of subjects: 72
Study: 37933882

Group type: EXPERIMENTAL
Intervention: AREN0533
Number of subjects: 148

Group type: COMPARATOR
Intervention: NWTS-5
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Pooled cohort
Number of subjects: 148
Study: 37933898

Group type: EXPERIMENTAL
Intervention: Holmium laser efficiency with Laryngeal Mask Airway (LMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Holmium laser efficiency with Endotracheal Intubation (ETI)
Number of subjects: 0
Study: 37933978

Group type: EXPERIMENTAL
Intervention: Spirometry-based motivational intervention (IG)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Brief smoking cessation counselling (CG)
Number of subjects: 614
Study: 37934000

Group type: EXPERIMENTAL
Intervention: Targeted therapy under investigation in basket trials
Number of subjects: 0
Study: 37934289

Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 0
Study: 37934301

Group type: EXPERIMENTAL
Intervention: Peloidotherapy (15 sessions for 3 weeks, 5 days a week)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) (3 sessions for 3 weeks, once a week, 1.8 bar, 10.0 Hz, 2000 impulses)
Number of subjects: 90
Study: 37934400

Group type: EXPERIMENTAL
Intervention: Individualized mat-Pilates sessions (45 min, twice weekly)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Home-based general exercise program (Control Group)
Number of subjects: 63
Study: 37934530

Group type: EXPERIMENTAL
Intervention: Specialty TUD services (including behavioral counseling and medications for tobacco treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 18
Study: 37934561

Group type: EXPERIMENTAL
Intervention: SALIENCE training (30 minutes, 3 times a week for 2 weeks, total of 6 sessions)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no SALIENCE training)
Number of subjects: 62
Study: 37934566

Group type: EXPERIMENTAL
Intervention: DWELL intervention (Facebook group providing practical solutions for home design for wellness)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control group (waitlist, no intervention)
Number of subjects: 643
Study: 37934572

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) system for personalized pain management recommendations
Number of subjects: 0
Study: 37934573

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 37934611

Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738) 160 mg twice daily for 2 weeks in a 4-weekly cycle
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738) at doses of 20-240 mg BD continuously or intermittently
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738)
Number of subjects: 67
Study: 37934880

Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 10
Study: 37934948

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 4595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4595
Study: 37935109

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (≤20 ng/mL)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Adjusted for age and paclitaxel schedule
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Vitamin D-deficient diet in mice
Number of subjects: 1191